AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 202 min read$LH

Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln

LabCorp (LH) will acquire Myriad Genetics' (MYGN) prenatal testing business for $210M in cash plus inventory value. The deal includes products like Prequel and Foresight. LabCorp expects $160M in revenue the first year and slight earnings accretion. Myriad plans to invest proceeds in cancer care. The transaction is expected to close by early 2027.

Original reporting
rttnews.com
Published Oct 20, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln — source image
Source · rttnews.com
Decision brief

The 30-second read

$LHBullishMed
01

Why it matters

The transaction adds $160M of revenue in year one for Labcorp and is slightly accretive to earnings, while Myriad will lose a niche but potentially high‑margin business.

02

Market read

First‑report of a $210M M&A deal in the healthcare sector, likely moving both stocks in the short term.

03

What to watch

Potential regulatory scrutiny of the prenatal testing market and the impact on Myriad's remaining oncology pipeline.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Labcorp (LH) is a leading provider of clinical laboratory services; Myriad Genetics (MYGN) focuses on molecular diagnostics and oncology.

Company-level read

Ticker impact

$LHBullishHigh confidence
Context

Labcorp announced a $210M cash acquisition of Myriad Genetics' prenatal testing business, expected to be slightly accretive to earnings.

Expected impact

potential upside as the market prices in the accretive acquisition

Evidence & confidence

First‑report of a mid‑size M&A with clear revenue and earnings benefits; investors typically bid up the acquirer.

$MYGNBearishHigh confidence
Context

Myriad Genetics agreed to sell its prenatal testing portfolio to Labcorp for $210M, removing a non‑core segment.

Expected impact

downward pressure as the market reacts to loss of a revenue stream

Evidence & confidence

The sale is a material carve‑out; investors often penalize sellers for losing a growth segment.

Market effects

Sector

Strengthens Labcorp's position in the specialty diagnostics sector while shrinking Myriad's prenatal footprint.

Regional

U.S. healthcare M&A activity may see modest uplift as the deal signals continued consolidation.

Global

Limited to U.S. biotech and diagnostics markets; no broader macro effect.

Counterpoint

What could challenge this read

The acquisition could be over‑priced; integration risk may outweigh the modest revenue boost.

Key entities

  • Company
    Labcorp Holdings Inc.

    Acquirer, U.S. clinical laboratory services provider.

  • Company
    Myriad Genetics Inc.

    Seller, molecular diagnostics firm.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$MYGNHighAI 9/10

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

investorideas.com2 min
OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min